title: Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
abstract: Background Romidepsin is a novel histone deacetylase inhibitor that is approved for the treatment of cutaneous and peripheral T-cell lymphoma in patients who have had at least one prior therapy. Romidepsin is generally well tolerated, though it comes with a risk of cardiac toxicities. Objective We report a case of electrocardiogram changes in a 64-year-old male with enteropathy-associated T-cell lymphoma, type 2, treated with salvage romidepsin therapy who relapsed after non-myeloablative allogeneic sibling peripheral blood stem cell transplant. Discussion Although histone deacetylase inhibitors have been investigated for many years, they have only recently been translated to clinical use as a therapy for malignancies. Furthermore, given their approval for a rare disease, clinicians often have limited experience with the dosing and side effects of histone deacetylase inhibitors. Conclusion This case report and literature review investigates the cardiac side effects of histone deacetylase inhibitors and illustrates the importance of cardiac monitoring prior to and during treatment.
authors.affiliation: 1 Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA.|2 Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
authors.forename: Zachary T
authors.initials: ZT
authors.lastname: Rivers
authors.affiliation: 3 Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
authors.forename: Drew R
authors.initials: DR
authors.lastname: Oostra
authors.affiliation: 1 Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA.
authors.forename: James S
authors.initials: JS
authors.lastname: Westholder
authors.affiliation: 3 Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Vercellotti
mesh_terms: D066126:Cardiotoxicity; D047630:Depsipeptides / Q000009:adverse effects*; D004562:Electrocardiography / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects*; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C087123:romidepsin
keywords: ECG changes; HDAC inhibitors; Romidepsin; cardiac toxicity